Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW JAMES ZIRWAS

Allopathic & Osteopathic Physicians Dermatology

NPI
1699741876
CMS profile
76317
Location
BEXLEY, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$745,357.89

625 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW JAMES ZIRWAS

NPI 1699741876 · CMS profile ID 76317

Allopathic & Osteopathic Physicians / Dermatology

BEXLEY, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW JAMES ZIRWAS, NPI 1699741876, CMS profile ID 76317. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MATTHEW JAMES ZIRWAS, NPI 1699741876, CMS profile ID 76317. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MATTHEW JAMES ZIRWAS, NPI 1699741876, CMS profile ID 76317, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

625 matching records · $745,357.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 625 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 625.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $121.1308/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044491497 CMS
Incyte Corporation $1,400.0008/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044491783 CMS
Incyte Corporation $5,600.0008/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044491857 CMS
AbbVie Inc. $4,725.0008/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868781 CMS
AbbVie Inc. $96.0008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868769 CMS
AbbVie Inc. $903.6808/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868773 CMS
LEO Pharma Inc. $81.4408/09/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053546691 CMS
LEO Pharma Inc. $22.0008/09/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053546697 CMS
LEO Pharma Inc. $7,120.0008/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053546703 CMS
AbbVie Inc. $62.9908/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868753 CMS
AbbVie Inc. $480.0708/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868759 CMS
Dermavant Sciences, Inc. $1,600.0008/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991272031 CMS
Incyte Corporation $4.2508/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044491885 CMS
Regeneron Healthcare Solutions, Inc. $3,699.0008/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570802 CMS
Regeneron Healthcare Solutions, Inc. $3,699.0008/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570807 CMS
Regeneron Healthcare Solutions, Inc. $3,699.0008/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570815 CMS
AbbVie Inc. $8.4308/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868745 CMS
Dermavant Sciences, Inc. $126.1808/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991272015 CMS
Dermavant Sciences, Inc. $496.0008/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991272019 CMS
Dermavant Sciences, Inc. $50.0408/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991272023 CMS
Dermavant Sciences, Inc. $666.3008/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991272027 CMS
Dermavant Sciences, Inc. $1,600.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991272011 CMS
Janssen Biotech, Inc. $124.3108/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988493465 CMS
Regeneron Healthcare Solutions, Inc. $3,699.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570789 CMS
Regeneron Healthcare Solutions, Inc. $8,220.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570795 CMS
Incyte Corporation $6,300.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044493000 CMS
LEO Pharma Inc. $118.4908/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053546673 CMS
LEO Pharma Inc. $186.0008/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053546681 CMS
LEO Pharma Inc. $629.8008/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053546685 CMS
Lilly USA, LLC $2,400.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031840543 CMS
AbbVie Inc. $7.8808/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868737 CMS
Incyte Corporation $109.8008/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044491793 CMS
Incyte Corporation $1,257.6308/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044491867 CMS
Regeneron Healthcare Solutions, Inc. $360.3308/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570753 CMS
Regeneron Healthcare Solutions, Inc. $205.9008/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570761 CMS
Regeneron Healthcare Solutions, Inc. $514.7508/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570766 CMS
Regeneron Healthcare Solutions, Inc. $308.8508/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570775 CMS
Regeneron Healthcare Solutions, Inc. $728.9008/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570781 CMS
Regeneron Healthcare Solutions, Inc. $301.6807/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570737 CMS
Regeneron Healthcare Solutions, Inc. $38.9707/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570747 CMS
Regeneron Healthcare Solutions, Inc. $121.8207/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570731 CMS
Dermavant Sciences, Inc. $1,600.0007/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991272007 CMS
PFIZER INC. $797.3507/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049272575 CMS
Regeneron Healthcare Solutions, Inc. $19.1307/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570718 CMS
Regeneron Healthcare Solutions, Inc. $109.3807/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570725 CMS
Regeneron Healthcare Solutions, Inc. $17.8707/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999570713 CMS
AbbVie Inc. $9.9507/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999868729 CMS
GENZYME CORPORATION $25.3007/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049978263 CMS
Arcutis Biotherapeutics, Inc. $750.0007/21/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044794703 CMS
PFIZER INC. $3,900.0007/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049330239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $263,269.10 273
PY2020 $155,391.12 127
PY2021 $282,005.54 223
PY2022 $648,399.44 543
PY2023 $745,357.89 625
PY2024 $706,840.10 522
PY2025 $488,574.90 353

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $31,097.00 6
PY2025 Principal investigator $807,992.60 402
PY2024 Recipient $57,020.00 9
PY2024 Principal investigator $509,094.77 788
PY2023 Recipient $8,134.02 2
PY2023 Principal investigator $570,650.57 397
PY2022 Recipient $729.00 3
PY2022 Principal investigator $401,812.93 108
PY2021 Recipient $91,830.95 17
PY2021 Principal investigator $608,899.39 53
PY2020 Recipient $145,958.01 13
PY2020 Principal investigator $356,072.29 79
PY2019 Recipient $315,294.23 25
PY2019 Principal investigator $850,245.17 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

408 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,420.25 12/17/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289866
Principal investigator 1 Janssen Research & Development, LLC $2,560.00 12/15/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161365
Principal investigator 1 ABBVIE INC. $16,870.30 12/04/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526692
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 12/03/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223289178
Principal investigator 1 Incyte Corporation $2.12 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509536
Principal investigator 1 Incyte Corporation $22.90 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509540
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509544
Principal investigator 1 Incyte Corporation $22.90 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509549
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509572
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509577
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509581
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509585
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509589
Principal investigator 1 Incyte Corporation $137.40 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509593
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509598
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509603
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509607
Principal investigator 1 Incyte Corporation $270.80 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509620
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509624
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509627
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509631
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509635
Principal investigator 1 Incyte Corporation $10.60 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509638
Principal investigator 1 Incyte Corporation $4.86 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509642
Principal investigator 1 Incyte Corporation $32.36 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509654
Principal investigator 1 Incyte Corporation $32.36 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509660
Principal investigator 1 Incyte Corporation $8.22 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509669
Principal investigator 1 Incyte Corporation $8.22 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509673
Principal investigator 1 Incyte Corporation $8.22 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509677
Principal investigator 1 Incyte Corporation $8.22 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509681
Principal investigator 1 Incyte Corporation $49.36 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509717
Principal investigator 1 Incyte Corporation $124.54 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509729
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509734
Principal investigator 1 Incyte Corporation $54.76 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509738
Principal investigator 1 Incyte Corporation $16.18 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509746
Principal investigator 1 Incyte Corporation $54.51 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509754
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509781
Principal investigator 1 PFIZER INC. $5,136.75 11/26/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228706991
Principal investigator 1 PFIZER INC. $2,498.96 11/26/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707433
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,543.82 11/19/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223288585
Principal investigator 1 PFIZER INC. $12,906.68 11/18/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228707335
Principal investigator 1 SANOFI US SERVICES INC. $4,956.00 11/17/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080262
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,714.16 11/12/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288285
Principal investigator 1 ABBVIE INC. $23,128.00 11/05/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522427
Principal investigator 1 Incyte Corporation $0.31 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509612
Principal investigator 1 Incyte Corporation $12.15 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509645
Principal investigator 1 Incyte Corporation $236.52 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509690
Principal investigator 1 Incyte Corporation $32.88 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509694
Principal investigator 1 Incyte Corporation $32.88 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509698
Principal investigator 1 Incyte Corporation $32.88 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509704
Principal investigator 1 Incyte Corporation $32.88 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509709
Principal investigator 1 Incyte Corporation $24.68 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509713
Principal investigator 1 Incyte Corporation $124.54 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509758
Principal investigator 1 Incyte Corporation $8.22 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509766
Principal investigator 1 Incyte Corporation $8.22 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509770
Principal investigator 1 Incyte Corporation $8.22 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509774
Principal investigator 1 Incyte Corporation $8.22 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509778
Principal investigator 1 Incyte Corporation $541.60 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509785
Principal investigator 1 Incyte Corporation $24.30 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509807
Principal investigator 1 Incyte Corporation $2.43 11/05/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509810
Principal investigator 1 PFIZER INC. $2,688.12 11/05/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707730
Principal investigator 1 Incyte Corporation $49.32 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509556
Principal investigator 1 Incyte Corporation $49.32 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509561
Principal investigator 1 Incyte Corporation $49.32 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509565
Principal investigator 1 Incyte Corporation $49.32 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509569
Principal investigator 1 Incyte Corporation $12.72 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509649
Principal investigator 1 Incyte Corporation $236.52 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509722
Principal investigator 1 Incyte Corporation $97.08 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509725
Principal investigator 1 Incyte Corporation $541.60 11/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509762
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,414.25 11/03/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287923
Principal investigator 1 PFIZER INC. $1,981.80 10/31/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228707163
Principal investigator 1 PFIZER INC. $1,435.73 10/29/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707537
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/27/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161308
Principal investigator 1 PFIZER INC. $4,970.55 10/22/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228706993
Principal investigator 1 PFIZER INC. $1,199.48 10/22/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,824.54 10/22/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223287247
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,622.42 10/17/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287127
Principal investigator 1 ABBVIE INC. $1,473.98 10/09/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202513861
Principal investigator 1 ABBVIE INC. $10,540.58 10/09/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516321
Principal investigator 1 PFIZER INC. $1,320.98 10/04/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707533
Principal investigator 1 Incyte Corporation $7.29 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509553
Principal investigator 1 Incyte Corporation $98.72 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509616
Principal investigator 1 Incyte Corporation $10.60 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509664
Principal investigator 1 Incyte Corporation $311.35 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509686
Principal investigator 1 Incyte Corporation $2.43 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509742
Principal investigator 1 Incyte Corporation $1.24 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509750
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509790
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509794
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509798
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509803
Principal investigator 1 PFIZER INC. $5,580.50 09/26/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707257
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 09/26/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 09/26/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285955
Principal investigator 1 PFIZER INC. $11,742.07 09/24/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228707535
Principal investigator 1 PFIZER INC. $740.30 09/24/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707814
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,763.44 09/24/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285866
Principal investigator 1 PFIZER INC. $2,756.71 09/19/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707716
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,954.46 09/19/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223285738
Principal investigator 1 PFIZER INC. $1,199.48 09/12/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707337
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 09/10/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285275
Principal investigator 1 PFIZER INC. $9,712.58 09/09/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228707069
Principal investigator 1 ABBVIE INC. $26,432.75 09/04/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509480
Recipient PFIZER INC. $940.00 09/04/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727127
Principal investigator 1 ABBVIE INC. $2,245.04 09/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507903
Principal investigator 1 Incyte Corporation $74.04 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509303
Principal investigator 1 Incyte Corporation $16.18 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509308
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509312
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509315
Principal investigator 1 Incyte Corporation $54.76 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509320
Principal investigator 1 Incyte Corporation $469.45 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509324
Principal investigator 1 Incyte Corporation $48.54 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509328
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509334
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509338
Principal investigator 1 Incyte Corporation $24.66 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509342
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509346
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509350
Principal investigator 1 Incyte Corporation $8.22 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509354
Principal investigator 1 Incyte Corporation $6.36 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509358
Principal investigator 1 Incyte Corporation $59.13 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509362
Principal investigator 1 Incyte Corporation $74.04 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509366
Principal investigator 1 Incyte Corporation $135.40 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509370
Principal investigator 1 Incyte Corporation $62.27 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509374
Principal investigator 1 Incyte Corporation $2.12 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509378
Principal investigator 1 Incyte Corporation $109.52 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509381
Principal investigator 1 Incyte Corporation $12.72 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509386
Principal investigator 1 Incyte Corporation $16.18 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509394
Principal investigator 1 Incyte Corporation $11.45 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509410
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509450
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509453
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509457
Principal investigator 1 Incyte Corporation $41.10 09/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509461
Recipient PFIZER INC. $3,200.00 08/25/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727453
Principal investigator 1 PFIZER INC. $4,081.06 08/23/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707910
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,372.99 08/22/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284559
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,991.02 08/20/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284437
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,524.18 08/20/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284439
Principal investigator 1 PFIZER INC. $18,054.86 08/09/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228707071
Principal investigator 1 ABBVIE INC. $38,040.20 08/06/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502917
Principal investigator 1 ABBVIE INC. $1,859.51 08/05/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501644
Principal investigator 1 PFIZER INC. $2,676.38 08/05/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707255
Principal investigator 1 Incyte Corporation $41.10 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509390
Principal investigator 1 Incyte Corporation $57.25 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509397
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509401
Principal investigator 1 Incyte Corporation $4.24 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509406
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509415
Principal investigator 1 Incyte Corporation $41.10 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509418
Principal investigator 1 Incyte Corporation $240.45 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509422
Principal investigator 1 Incyte Corporation $29.16 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509426
Principal investigator 1 Incyte Corporation $1.55 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509430
Principal investigator 1 Incyte Corporation $123.40 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509435
Principal investigator 1 Incyte Corporation $137.40 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509438
Principal investigator 1 Incyte Corporation $80.90 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509442
Principal investigator 1 Incyte Corporation $48.54 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509445
Principal investigator 1 Incyte Corporation $41.10 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509464
Principal investigator 1 Incyte Corporation $41.10 08/04/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509468
Principal investigator 1 PFIZER INC. $5,778.70 07/29/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707435
Principal investigator 1 Janssen Research & Development, LLC $3,235.00 07/28/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161322
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,390.53 07/23/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223283054
Principal investigator 1 PFIZER INC. $2,263.96 07/16/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707638
Principal investigator 1 SANOFI US SERVICES INC. $4,284.00 07/14/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080243
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,000.00 07/11/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282602
Principal investigator 1 ABBVIE INC. $26,633.01 07/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496813
Principal investigator 1 ABBVIE INC. $1,473.98 07/02/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495503
Principal investigator 1 SANOFI US SERVICES INC. $500.00 07/02/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080247
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509264
Principal investigator 1 Incyte Corporation $4.24 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509269
Principal investigator 1 Incyte Corporation $186.81 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509274
Principal investigator 1 Incyte Corporation $4.86 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509278
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509282
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509286
Principal investigator 1 Incyte Corporation $0.62 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509291
Principal investigator 1 Incyte Corporation $0.62 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509294
Principal investigator 1 Incyte Corporation $54.76 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509299
Principal investigator 1 Incyte Corporation $114.50 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509331
Principal investigator 1 Incyte Corporation $49.36 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509474
Principal investigator 1 Incyte Corporation $49.36 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509480
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509483
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509488
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509492
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509497
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509501
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509505
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509509
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509516
Principal investigator 1 Incyte Corporation $16.44 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509519
Principal investigator 1 Incyte Corporation $91.60 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509524
Principal investigator 1 Incyte Corporation $32.36 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509528
Principal investigator 1 Incyte Corporation $4.86 07/01/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509532
Principal investigator 1 PFIZER INC. $2,881.58 07/01/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707718
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,910.28 07/01/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282038
Principal investigator 1 PFIZER INC. $10,020.38 06/26/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228708706
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,616.30 06/25/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223281890
Principal investigator 1 SANOFI US SERVICES INC. $3,245.00 06/16/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080226
Principal investigator 1 ABBVIE INC. $2,584.22 06/12/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202491321
Principal investigator 1 ABBVIE INC. $364.00 06/10/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202490765
Principal investigator 1 SANOFI US SERVICES INC. $8,356.00 06/09/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080222
Principal investigator 1 ABBVIE INC. $5,898.55 06/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489379
Principal investigator 1 Incyte Corporation $17.51 06/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509148
Principal investigator 1 Incyte Corporation $25.75 06/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509173
Principal investigator 1 PFIZER INC. $5,105.04 05/29/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707640
Principal investigator 1 PFIZER INC. $26,041.18 05/29/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228707720
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,393.63 05/28/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280470
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $225.00 05/28/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280472
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 05/27/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080214
Principal investigator 1 Janssen Research & Development, LLC $1,952.00 05/26/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,250.47 05/21/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223280028
Principal investigator 1 PFIZER INC. $3,902.19 05/15/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707732
Recipient PFIZER INC. $330.00 05/08/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228759975
Principal investigator 1 ABBVIE INC. $30,193.60 05/07/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483163
Recipient PFIZER INC. $330.00 05/07/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760646
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,631.19 05/07/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223279122
Principal investigator 1 SANOFI US SERVICES INC. $4,515.00 05/05/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080210
Principal investigator 1 PFIZER INC. $8,087.04 05/03/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707812
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508989
Principal investigator 1 Incyte Corporation $4.24 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509066
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509091
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509107
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509111
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509115
Principal investigator 1 Incyte Corporation $0.62 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509119
Principal investigator 1 Incyte Corporation $49.36 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509122
Principal investigator 1 Incyte Corporation $118.26 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509126
Principal investigator 1 Incyte Corporation $9.72 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509130
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509133
Principal investigator 1 Incyte Corporation $311.35 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509137
Principal investigator 1 Incyte Corporation $125.95 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509141
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509145
Principal investigator 1 Incyte Corporation $34.35 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509152
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509157
Principal investigator 1 Incyte Corporation $125.95 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509161
Principal investigator 1 Incyte Corporation $54.76 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509184
Principal investigator 1 Incyte Corporation $6.36 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509221
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509229
Principal investigator 1 Incyte Corporation $32.36 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509233
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509240
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509243
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509247
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509251
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509255
Principal investigator 1 Incyte Corporation $16.44 05/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509259
Principal investigator 1 PFIZER INC. $6,533.19 05/02/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $964.65 05/01/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278786
Principal investigator 1 Janssen Research & Development, LLC $2,634.00 04/28/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161336
Principal investigator 1 SANOFI US SERVICES INC. $3,025.00 04/28/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080202
Principal investigator 1 SANOFI US SERVICES INC. $13,048.00 04/28/2025 Non-covered Recipient Entity
Probity Medical Research Corp
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226080206
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,815.78 04/11/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277966
Principal investigator 1 PFIZER INC. $651.25 04/08/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707159
Principal investigator 1 ABBVIE INC. $22,946.55 04/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202473597
Principal investigator 1 ABBVIE INC. $1,434.98 04/03/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202473601
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,000.00 04/02/2025 Non-covered Recipient Entity
Bexley Derm: Dermatologists of Greater Columbus
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163710
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508985
Principal investigator 1 Incyte Corporation $24.30 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508992
Principal investigator 1 Incyte Corporation $177.39 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508996
Principal investigator 1 Incyte Corporation $57.25 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509000
Principal investigator 1 Incyte Corporation $1.55 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509004
Principal investigator 1 Incyte Corporation $80.90 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509008
Principal investigator 1 Incyte Corporation $123.40 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509011
Principal investigator 1 Incyte Corporation $14.58 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509015
Principal investigator 1 Incyte Corporation $4.86 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509020
Principal investigator 1 Incyte Corporation $0.62 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509025
Principal investigator 1 Incyte Corporation $15.45 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509028
Principal investigator 1 Incyte Corporation $91.60 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509032
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509037
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509041
Principal investigator 1 Incyte Corporation $4.12 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509045
Principal investigator 1 Incyte Corporation $49.36 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509050
Principal investigator 1 Incyte Corporation $79.50 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509054
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509058
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509062
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509070
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509074
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509078
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509083
Principal investigator 1 Incyte Corporation $106.00 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509087
Principal investigator 1 Incyte Corporation $53.00 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509095
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509099
Principal investigator 1 Incyte Corporation $116.60 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509103
Principal investigator 1 Incyte Corporation $62.27 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509165
Principal investigator 1 Incyte Corporation $43.04 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509169
Principal investigator 1 Incyte Corporation $32.36 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509179
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509187
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509194
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509198
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509202
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509206
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509210
Principal investigator 1 Incyte Corporation $41.10 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509213
Principal investigator 1 Incyte Corporation $143.10 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509217
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509224
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240509235
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,669.38 03/26/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277047
Principal investigator 1 Janssen Research & Development, LLC $2,246.00 03/24/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $675.00 03/19/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223276843
Principal investigator 1 ABBVIE INC. $19,198.85 03/07/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460387
Principal investigator 1 Arcutis Biotherapeutics, Inc. $750.00 03/07/2025 Non-covered Recipient Entity
Bexley Derm: Dermatologists of Greater Columbus
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163708
Principal investigator 1 ABBVIE INC. $3,641.02 03/06/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202457330
Principal investigator 1 ABBVIE INC. $473.20 03/06/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202457410
Principal investigator 1 ABBVIE INC. $1,440.00 03/06/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202457415
Principal investigator 1 Janssen Research & Development, LLC $2,128.00 03/06/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161351
Principal investigator 1 PFIZER INC. $4,894.96 03/05/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228706989
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508809
Principal investigator 1 Incyte Corporation $14.58 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508813
Principal investigator 1 Incyte Corporation $9.72 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508816
Principal investigator 1 Incyte Corporation $1.86 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508821
Principal investigator 1 Incyte Corporation $57.25 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508824
Principal investigator 1 Incyte Corporation $148.08 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508829
Principal investigator 1 Incyte Corporation $1.24 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508833
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508837
Principal investigator 1 Incyte Corporation $148.85 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508841
Principal investigator 1 Incyte Corporation $16.18 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508845
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508880
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508884
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508888
Principal investigator 1 PFIZER INC. $25,493.35 03/01/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707333
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,361.15 02/26/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275635
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $209.25 02/24/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275503
Principal investigator 1 Janssen Research & Development, LLC $2,949.00 02/21/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161328
Principal investigator 1 PFIZER INC. $7,310.02 02/13/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228752545
Principal investigator 1 ABBVIE INC. $30,885.38 02/12/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SOUTHWEST OHIO INC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202450614
Principal investigator 1 PFIZER INC. $41,716.41 02/08/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228707161
Principal investigator 1 ABBVIE INC. $385.53 02/05/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202444196
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,337.55 02/05/2025 Non-covered Recipient Entity
Bexley Derm: Dermatologists of Greater Columbus
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163706
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,909.36 02/05/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,875.00 02/05/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,995.70 02/05/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274855
Principal investigator 1 Janssen Research & Development, LLC $2,776.00 01/27/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175161374
Principal investigator 1 Amgen Inc. $6,749.40 01/21/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY RESEARCH
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) No dispute reported 06/30/2026 1246639619
Principal investigator 1 ABBVIE INC. $3,430.01 01/15/2025 Non-covered Recipient Entity
DERMATOLOGISTS OF SW OHIO LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202438629
Principal investigator 1 PFIZER INC. $546.00 01/14/2025 Non-covered Recipient Entity
Probity Medical Research Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228799663
Recipient Eli Lilly and Company $15,923.00 01/09/2025 Covered Recipient Physician AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187871887
Recipient Eli Lilly and Company $10,374.00 01/09/2025 Covered Recipient Physician A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187871889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,658.85 01/08/2025 Non-covered Recipient Entity
PROBITY MEDICAL RESEARCH CORP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273799
Principal investigator 1 Amgen Inc. $19,918.33 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639617
Principal investigator 1 Incyte Corporation $109.52 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508619
Principal investigator 1 Incyte Corporation $1.24 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508623
Principal investigator 1 Incyte Corporation $206.70 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508627
Principal investigator 1 Incyte Corporation $196.10 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508631
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508635
Principal investigator 1 Incyte Corporation $217.30 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508638
Principal investigator 1 Incyte Corporation $4.86 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508642
Principal investigator 1 Incyte Corporation $2.43 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508646
Principal investigator 1 Incyte Corporation $68.70 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508649
Principal investigator 1 Incyte Corporation $153.70 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508654
Principal investigator 1 Incyte Corporation $127.20 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508658
Principal investigator 1 Incyte Corporation $100.70 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508662
Principal investigator 1 Incyte Corporation $100.70 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508666
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508670
Principal investigator 1 Incyte Corporation $148.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508674
Principal investigator 1 Incyte Corporation $68.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508679
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508684
Principal investigator 1 Incyte Corporation $121.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508689
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508693
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508698
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508702
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508707
Principal investigator 1 Incyte Corporation $47.70 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508711
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508715
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508719
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508724
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508727
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508732
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508736
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508741
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508746
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508750
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508754
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508756
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508759
Principal investigator 1 Incyte Corporation $57.25 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508763
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508767
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508771
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508775
Principal investigator 1 Incyte Corporation $6.18 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508779
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508783
Principal investigator 1 Incyte Corporation $32.36 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508788
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508792
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508794
Principal investigator 1 Incyte Corporation $22.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508798
Principal investigator 1 Incyte Corporation $103.05 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508804
Principal investigator 1 Incyte Corporation $48.42 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508848
Principal investigator 1 Incyte Corporation $49.36 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508852
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508856
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508860
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508863
Principal investigator 1 Incyte Corporation $498.16 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508867
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508871
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508875
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508895
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508897
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508902
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508906
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508910
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508916
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508920
Principal investigator 1 Incyte Corporation $58.30 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508924
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508928
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508933
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508938
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508943
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508947
Principal investigator 1 Incyte Corporation $59.13 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508951
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508955
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508961
Principal investigator 1 Incyte Corporation $2.06 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508965
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508969
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508973
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508977
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
BEXLEY DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240508982